MDxHealth SA - Company Profile
Powered by 
All the data and insights you need on MDxHealth SA in one report.
$295
- Save hours of research time and resources with
our up-to-date MDxHealth SA Strategy Report
- Understand MDxHealth SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment, and the personalized treatment of patients. The company’s product portfolio includes ConfirmMDx, an epigenetic assay that detects the epigenetic effect of cancer; SelectMDx, a liquid biopsy assay for prostate cancer. MdxHealth tests are based on MSP (Methylation-Specific polymerase chain reaction) technology, a proprietary DNA-based platform. It also offers biomarker development services to many pharmaceutical companies. MDxHealth markets its products through sales forces, partnerships and distributors. The company has operations in the Netherlands, Belgium, and the US. MDxHealth is headquartered in Herstal, Liege, Belgium.
Headquarters
Belgium
Address
Cap Business Center, Rue D'Abhooz 31, Herstal, 4040
Website
mdxhealth.com
Telephone
32 4 3642070
No of Employees
258
Industry
Medical Equipment
Ticker Symbol & Exchange
MDXH (NASD)
Revenue (2022)
$70.2M
89.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
2.1%
(2022 vs 2021)
Market Cap*
$67.4M
Net Profit Margin (2022)
XYZ
48.3%
(2022 vs 2021)
* As of and is in US$
MDxHealth SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| SelectMDx - Prostate Cancer | Development of Companion Diagnostics | SelectMDx |
| ConfirmMDx - prostate cancer | Biomarker Discovery Services | ConfirmMDx |
| Technology: | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In January, the company provided supplemental information related to its acquisition of the Oncotype DX GPS test. |
| 2022 | Acquisitions/Mergers/Takeovers | In August, the company acquired Oncotype DX GPS prostate cancer testing business from Exact Sciences. |
| 2021 | Stock Listings/IPO | In November, the company announced its plans to raise US$45 million in an IPO. |
Competitor Comparison
| Key Parameters | MDxHealth SA | OPKO Health Inc | Myriad Genetics Inc | Epigenomics AG | Agendia NV |
|---|---|---|---|---|---|
| Headquarters | Belgium | United States of America | United States of America | Germany | Netherlands |
| City | Herstal | Miami | Salt Lake City | Berlin | Amsterdam |
| State/Province | - | Florida | Utah | Baden-Wurttemberg | Noord-Holland |
| No. of Employees | 258 | 3,930 | 2,700 | 18 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Koen Hoffman | Chairman | Executive Board | 2018 | 54 |
| Michael K. McGarrity | Chief Executive Officer; Director | Executive Board | 2019 | 60 |
| Ron Kalfus | Chief Financial Officer | Senior Management | 2019 | 48 |
| John Bellano | Chief Commercial Officer | Senior Management | 2019 | 54 |
| Joseph Sollee | General Counsel; Executive Vice President - Corporate Development and Legal Affairs | Senior Management | 2008 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer